HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Free to Access Full Text Full Text (PDF) All Versions of this Article: ard.2007.071605v1 67/4/511    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Visvanathan, S Articles by Braun, J Search for Related Content PubMed PubMed Citation Articles by Visvanathan, S Articles by Braun, J Topic Collections Unlocked

Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab

¹ Centocor Research and Development, Inc., Malvern, PA, USA
² Department of Rheumatology, Leiden University Medical Centre, The Netherlands
³ Rheumazentrum-Ruhrgebiet, Herne, Germany

Correspondence to:
Sudha Visvanathan, PhD, 200 Great Valley Parkway, Malvern, PA 19355, USA; svisvana{at}cntus.jnj.com

Objective: To evaluate the relationship between biomarker levels and disease activity and the spinal inflammation detected by magnetic resonance imaging (MRI) in patients with ankylosing spondylitis (AS).

Methods: Patients with AS were randomly assigned in a 3:8 ratio to receive infusions of placebo or 5 mg/kg infliximab at weeks 0, 2, 6, 12 and 18. Sera were collected for biomarker analysis at weeks 0, 2 and 24 and were analysed for levels of interleukin-6 (IL-6), vascular endothelial growth factor (VEGF) and C-reactive protein (CRP). Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores and pre- and post-gadolinium T1 and short inversion recovery MRIs were collected at baseline and week 24.

Results: Significantly greater reductions in IL-6, VEGF and CRP were observed at weeks 2 and 24 in the infliximab group compared with the placebo group (all p<0.001). Baseline IL-6 levels >7.38 pg/ml and CRP levels >1.5 mg/dl were associated with increased rates of clinical response after 24 weeks. Multiple regression analyses showed that reductions from baseline to week 2 in IL-6, but not CRP or VEGF, were significantly associated with reductions in MRI activity and BASDAI scores from baseline to week 24 in the infliximab group (p<0.001).

Conclusions: Significant reductions in IL-6, VEGF and CRP were observed with infliximab compared with placebo. High levels of baseline IL-6 and CRP were associated with clinical response after infliximab treatment. Early reductions in IL-6 were significantly associated with improvements in disease activity and the spinal inflammation detected by MRI.

This article has been cited by other articles:

				M. R. Saban, J. M. Backer, M. V. Backer, J. Maier, B. Fowler, C. A. Davis, C. Simpson, X.-R. Wu, L. Birder, M. R. Freeman, et al. VEGF receptors and neuropilins are expressed in the urothelial and neuronal cells in normal mouse urinary bladder and are upregulated in inflammation Am J Physiol Renal Physiol, July 1, 2008; 295(1): F60 - F72. [Abstract] [Full Text] [PDF]

				D. J. Pradeep, A. Keat, and K. Gaffney Predicting outcome in ankylosing spondylitis Rheumatology, July 1, 2008; 47(7): 942 - 945. [Full Text] [PDF]